TB-500 (Thymosin Beta-4) 10mg
A 43-amino-acid acetylated synthetic Thymosin Beta-4, supplied lyophilized for in vitro actin-binding and cell-migration research.
20 in stock
What is TB-500?
TB-500 is a synthetic 43-amino-acid acetylated peptide corresponding to thymosin β-4 (Tβ4), a naturally occurring actin-sequestering protein. It binds monomeric G-actin through the central LKKTETQ motif, regulating the cytoplasmic actin pool available for filament elongation, and is studied for its role in cell migration and angiogenesis signaling. Its low molecular weight, absence of disulfide bonds, and lack of extracellular-matrix binding let it cross tissue compartments readily in research models.
Research areas where laboratories buy TB-500 for in vitro work include actin pharmacology separating Tβ4 effects from those of its Ac-SDKP cleavage fragment, migration and scratch assays in dermal fibroblasts, keratinocytes and corneal epithelial cells, angiogenesis readouts in HUVEC tube-formation and aortic-ring models, cardiac and skeletal-muscle models in rodents, and cytoskeletal imaging with fluorescent G-actin and F-actin reporters. TB-500 / thymosin β-4 is not approved by the FDA for any indication.
Every lot, independently verified
Compound information
Chemical & structural reference data — specifications, molecular profile and handling.
TB-500 Mechanism of Action
- Binds monomeric G-actin through the central LKKTETQ motif, sequestering actin monomers and modulating the cytoplasmic pool available for filament elongation.
- Promotes endothelial migration, tube formation, and vessel-network density in HUVEC tube-formation and aortic-ring angiogenesis models.
- Engages the N-terminal Ac-SDKP cleavage pathway, where prolyl oligopeptidase liberates the tetrapeptide that carries its own hematopoiesis and fibrosis activity.
- Crosses tissue compartments readily — low molecular weight, no disulfide bonds, no extracellular-matrix binding.
- Studied for epicardial progenitor activation and fibrosis-marker expression in rodent cardiac ischemia-reperfusion models.
TB-500 Research Applications
- Actin pharmacology — separating Tβ4 effects dependent on the LKKTETQ motif from those of the Ac-SDKP tetrapeptide.
- Migration and scratch assays in dermal fibroblasts, keratinocytes, and corneal epithelial cells.
- Angiogenesis readouts in HUVEC tube-formation and aortic-ring models.
- Cardiac and skeletal-muscle models in rodents, including ischemia-reperfusion designs.
- Cytoskeletal imaging with fluorescent G-actin and F-actin reporters tracking the polymerization equilibrium.
Why Buy TB-500 from Koi Peptides?
- Every batch of Koi TB-500 is synthesized and lyophilized in the United States, then released against independent third-party laboratory (Freedom Diagnostics Testing) testing.
- Each lot is tested by HPLC for purity, LC-MS for identity confirmation, and screened for endotoxin before release.
- The lot ID is printed on every vial and ties back to a public COA library, so researchers can verify documentation before they buy and after the vial arrives.
- Orders placed before 2 PM CT ship the same business day, and shipping is free on orders over $200.
References
View all references +
- Safer, D., et al. (1991). Thymosin β4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry, 266(7), 4029–4032.
- Crockford, D., et al. (2010). Thymosin β4: structure, function, and biological properties. Annals of the New York Academy of Sciences, 1194, 179–189. doi.org/10.1111/j.1749-6632.2010.05492.x
- Malinda, K. M., et al. (1997). Thymosin β4 stimulates directional migration of human umbilical vein endothelial cells. FASEB Journal, 11(6), 474–481. doi.org/10.1096/fasebj.11.6.9194528
- Smart, N., et al. (2007). Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature, 445(7124), 177–182. doi.org/10.1038/nature05383
- Xue, B., & Robinson, R. C. (2013). Guardians of the actin monomer. European Journal of Cell Biology, 92(10–11), 316–332. doi.org/10.1016/j.ejcb.2013.10.012
- Cavasin, M. A., et al. (2004). Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension, 43(5), 1140–1145. doi.org/10.1161/01.HYP.0000126172.01673.84
- Liu, J. M., et al. (2003). Ac-SDKP is generated from thymosin β4 in vivo by ACE N domain. Journal of Biological Chemistry, 278(40), 38513–38520. doi.org/10.1074/jbc.M209853200
- Sosne, G., et al. (2010). Biological activities of thymosin β4 defined by active sites in short peptide sequences. FASEB Journal, 24(7), 2144–2151. doi.org/10.1096/fj.09-142307
Regulatory Status
Regulatory status — provided for research context.
Regulatory Status
This research-grade material is supplied by Koi Peptides for laboratory research only. It is not approved by the FDA for any indication, and is not formulated, packaged or labeled as a drug, food or cosmetic.
For laboratory and research use only. Not for human consumption. This product is not a drug, food or cosmetic. It is sold exclusively to qualified researchers and licensed laboratories. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Frequently Asked Questions About TB-500
What is TB-500 used for in research?+
What purity is Koi's TB-500?+
How do I prepare a solution of TB-500?+
What is the CAS number for TB-500?+
Is TB-500 for human use?+
Does TB-500 come with a Certificate of Analysis?+
How should TB-500 be stored?+
Stock your lab with Koi
Research-grade peptides — made in the USA, third-party tested, with public lot-matched COAs. Shop the catalog, or contact our team with questions.



